The volume-outcome relationship in kidney cancer: is more really better?

Brian T. Kadow, Shreyas S. Joshi, Alexander Kutikov, Elizabeth Handorf, Marc C. Smaldone, Robert G. Uzzo, Daniel M. Geynisman

Fox Chase Cancer Center, Philadelphia, PA, USA

Correspondence to: Daniel M. Geynisman. Fox Chase Cancer Center, 333 Cottman Ave., Philadelphia, PA 19111, USA. Email: daniel.geynisman@fccc.edu.

Provenance: This is an invited article commissioned by the Section Editor Dr. Xiao Li (Department of Urology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China).


Submitted Sep 11, 2019. Accepted for publication Sep 18, 2019.
doi: 10.21037/atm.2019.09.108
View this article at: http://dx.doi.org/10.21037/atm.2019.09.108

Multiple studies have suggested a correlation between hospital surgical volume and clinical outcomes, including oncologic outcomes such as cancer-specific survival (1,2). The fact that high-volume surgeons and institutions have superior outcomes may be related to improved technical surgical experience, streamlined perioperative protocols, access to multidisciplinary care, or the availability of new treatment modalities through clinical trials. This phenomenon has been reported in the literature across a range of disease states and surgical interventions (3-9). This volume-outcome relationship, which has been studied since the late 1970’s, has led many to advocate for the regionalization of complex cancer surgery (10,11). Many of these studies, however, have been limited in the length of follow-up and have only reported perioperative and short-term (30 day) outcomes (12). However, more relevant cancer-related quality metrics might be evaluated through longer-term follow-up, such as 1- or 5-year cancer-specific survival or overall survival (OS).

Within the urologic literature, the effect of regionalization of care for renal cell carcinoma (RCC) has been studied in both patients with localized and metastatic disease. These studies suggest improved perioperative outcomes such as lower complication rates, fewer blood transfusions and shorter length of stay at high-volume centers, as well as improved survival outcomes for patients with metastatic disease receiving systemic therapy (13-15). Adding to the volume-outcome literature for RCC, Hsu and colleagues recently published a retrospective administrative database study evaluating the relationship between a hospital’s surgical volume for treatment of RCC and short, intermediate, and long-term overall mortality (16). They identified 12,912 adults with a diagnosis of clinically localized RCC who underwent surgical intervention between 2000 and 2010 within the National Health Service (NHS) system in the United Kingdom. Annual operative caseloads were calculated, and hospitals were categorized into low (<20 cases), medium (20–39 cases), or high (≥40 cases) volume centers based on their annual radical or partial nephrectomy surgical volume. Univariate and multivariate models were used to evaluate the relationship between surgical volume and short (30 days–1 year), intermediate (1–3 years), and long-term (3–5 years) overall survival. All patients had at least 5 years of post-operative follow-up. The authors found that patients undergoing treatment at high volume institutions had more comorbidities, more stage T1 tumors, and on multivariable analyses, had superior short-term (up to 1 year) outcomes, with a 34% reduction in mortality hazard (HR, 0.66; 95% CI 0.53–0.83; P<0.01) over medium- or low-volume institutions. They calculated that 71 patients would need to be treated at a high-volume center to prevent 1 mortality during the first year.

Interestingly, however, the authors found that after 1 year
of follow-up, there did not appear to be a survival benefit for patients treated at high volume centers. Given that the analysis of each time period was dependent on patients surviving the previous follow-up interval, once a patient passed through the initial post-operative “bottleneck”, a center's clinical volume ceased to be a factor impacting their survival. Therefore, the differences in short-term (up to 30 days) mortality may be the main factor contributing to the superior mortality outcomes at high-volume institutions for up to 1 year. In subgroup analysis, the authors found attenuated, non-significant associations between hospital volume and mortality for patients with locally advanced (T3 or T4) disease, potentially suggesting that tumor biology may be a more important driver of outcomes in these patients.

This study by Hsu and colleagues is the first to demonstrate a survival benefit for surgical treatment of RCC at high volume centers beyond 30 days, as the previous literature has only evaluated perioperative and short-term outcomes. This study lends further credence to the view that regionalization of complex cancer care leads to superior clinically relevant outcomes. As the authors note, however, the exact factors that lead to improved outcomes at high-volume centers have not yet been elucidated, but they theorized it may be due to improved perioperative outcomes, standardization of perioperative pathways, availability of multidisciplinary care that is not available at lower volume centers, more rapid adoption of new clinical guidelines, or access to novel treatments through clinical trials. How to improve these factors at lower-volume centers is not entirely clear and warrants future study. For instance, assessment of outcomes of low-volume surgeons at high-volume centers, as has been done in prior work, could be informative (17).

The authors acknowledge their study limitations such as the low rate of complete TNM staging and the lack of knowledge of neoadjuvant or adjuvant systemic therapy, which could have significant implications for cancer-specific and overall survival. Another limitation of the study is the lack of RCC-specific mortality, particularly given the fact that the largest effect of hospital volume on mortality appeared to be in patients with T1 disease. In addition, the division of centers into low-, intermediate-, and high-volume is somewhat artificial. A continuous volume-outcome measure may be more robust. Another confounding finding in the study was that high-volume hospitals operated on a statistically higher rate of patients with T1 disease than lower volume centers, suggesting that high-volume hospitals in this study may have been less likely to offer active surveillance for small renal masses than their lower-volume counterparts. Furthermore, a higher rate of patients with T1 disease at high-volume centers could have an impact on impact mortality rates because these patients would be expected to have less complicated surgical procedures, lower intraoperative blood loss, and potentially shorter recovery times than in patients with higher stage (T2+) tumors.

Despite the study’s strengths, how these findings should be applied to clinical practice is unclear. Although regionalization of the care of RCC (and other complex oncologic) patients may be beneficial, it is extremely challenging to accomplish from both logistic and financial perspectives. While the call for regionalization may be a reasonable endorsement within the NHS system that formed the basis for this study, such regionalization would likely be impossible within the complex American healthcare environment. Furthermore, some have raised concerns that regionalization may create significant barriers to access of care for the most vulnerable of patient populations (18). Rather, promoting a closer relationship and partnership between centers of excellence and community sites so as to share and disseminate practice patterns and insights, hosting joint tumor boards, creating user-friendly clinical pathways, and leveraging technology to help improve the care of patients in the community may be a more reasonable approach.

Finally, as newer targeted agents and immunotherapy strategies become increasingly effective and more frequently utilized in patients with higher stage disease in the perioperative period, or in those patients who eventually progress to metastatic disease, these therapies may subsequently “level the playing field” and potentially minimize some of the effect that hospital surgical volume appears to have on survival metrics, particularly in the long-term setting. In the meantime, providers at lower-volume centers should not hesitate to “phone a friend” on behalf of their patient.

**Acknowledgments**

None.

**Footnote**

Conflicts of Interest: The authors have no conflicts of interest to declare.
Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References
